RJA
VTGN icon

Raymond James & Associates’s VistaGen Therapeutics VTGN Stock Holding History

Raymond James & Associates’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$52.4K – 3961
2023
Q3 		$52.4K Buy
+10,000
New +$44.4K ﹤0.01% 3669

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Raymond James & Associates's VTGN Position: Q4 2023 in Review

Raymond James & Associates sold out of VistaGen Therapeutics (VTGN) in Q4 2023, closing a stake of 10,000 shares — an estimated $52.4K sold.

Raymond James & Associates first reported a position in VTGN in Q3 2023 and held it in 1 quarter. The position peaked at $52.4K in Q3 2023. 46 funds tracked by Wall St. Rank hold VTGN as of Q4 2023.

  • Raymond James & Associates reported no remaining VistaGen Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,000 VistaGen Therapeutics shares in Q4 2023, an estimated $52.4K.
  • Raymond James & Associates first reported a position in VistaGen Therapeutics in Q3 2023 and held it in 1 quarter.
  • Raymond James & Associates's VistaGen Therapeutics position peaked at $52.4K in Q3 2023.
  • 46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.